Eli Lilly ink licensing pact with Sun Pharma, Cipla, Lupin to expedite COVID drug Baricitinib
Advertisement
New Delhi: Drug firm Eli Lilly and Company on Monday said it has inked voluntary licensing agreements with Indian drug firms -- Sun Pharma, Cipla and Lupin -- to expedite availability of its arthritis drug Baricitinib for treatment of COVID-19 patients in India.
The company "has issued royalty-free, non-exclusive voluntary licenses to established Indian pharmaceutical manufacturers of generic medicines, Cipla, Lupin and Sun Pharmaceutical Industries, who are collaborating with Lilly to accelerate and expand the availability of Baricitinib in India," Eli Lilly and Company said in a statement.
The company is also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licenses, it added.
"These voluntary licensing agreements will ensure high quality manufacturing and accessibility of Baricitinib during this pandemic improving the local treatment options available to positively impact the lives of people who are currently battling COVID-19 in India," Eli Lilly and Company said.
This is in addition to the donations being offered by Lilly to the Indian government that will potentially help alleviate the burden of COVID-19, Visini said.
The company had last week said that an initial donation of 4,00,000 Baricitinib tablets through the humanitarian aid organisation, Direct Relief, is being made immediately available to the Indian government for eligible hospitalised COVID-19 patients in India and that it will work urgently to increase the quantity of donated product multifold over the coming weeks.
Baricitinib is currently registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs.
Meanwhile, Eli Lilly and Company continues to engage in active dialogue with the regulatory authorities and government in India to donate its anti-COVID-19 treatments, including neutralising antibodies, the statement said.
On the development, Cipla MD and Global CEO Umang Vohra said, "Through the pandemic, Cipla has been at the forefront of COVID care and our partnership with Lilly is a demonstration of our unwavering commitment to care towards patients impacted by COVID-19."
In a similar vein, Sun Pharma, India business CEO Kirti Ganorkar said, "Through this collaboration, we aim to join our forces with Lilly to accelerate access to Baricitinib in India at a time when it is most needed".
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.